Previous 10 | Next 10 |
home / stock / mmedf / mmedf news
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD Canada NewsWire NEW YORK, Aug. 25, 2020 MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti Lab NEW YORK , Aug. 25, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OT...
In the news release, Mind Medicine (MindMed) Inc. (NEO: MMED)(DE: BGHM)(OTC:MMEDF) Announces Q2 2020 Financial Results, issued 14-Aug-2020 by Mind Medicine (MindMed) Inc. over PR Newswire, we are advised by the company that the second bullet of the Financial Highlights (in USD) sect...
In the news release, Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM) Announces Q2 2020 Financial Results, issued 14-Aug-2020 by Mind Medicine (MindMed) Inc. over PR Newswire, we are advised by the company that the second bullet of the Financial Highlights (in USD) sect...
/C O R R E C T I O N -- Mind Medicine (MindMed) Inc./ Canada NewsWire NEW YORK, Aug. 20, 2020 In the news release, Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results, issued 14-Aug-2020 by Mind Medicine (MindMed) Inc. over PR Newswire, we are advised by the c...
A team of researchers from Johns Hopkins University are calling on people who use psychedelics to enroll for their new study that is geared at understanding the real-world effects of taking psychedelic substances like shrooms (magic mushrooms). The Johns Hopkins researchers are working toget...
One business lawyer focused on mergers and acquisitions (M&A) expects to see large entities, such as pharmaceutical companies, enter the psychedelics space sooner rather than later. Kris Miks, partner at Norton Rose Fulbright Canada, said these potential entries will be fueled by a des...
Psychedelic drug treatments are quickly going mainstream, with new coverage surfacing from 60 Minutes . In fact, they speak about how psilocybin for example is helping participants do things like quitting smoking and worrying far less. “Early results are impressive, as are the experie...
Mind Medicine (MindMed) Inc (MMEDF) Q1 2020 Earnings Conference Call Aug 17, 2020 1:00 PM ET Company Participants Collin Gage - Head of Corporate Development JR Rahn - Co Founder, Director & Co CEO Stephen Hurst - Co Founder, Executive Chair & Co CEO Dave Guebert - Chi...
Mind Medicine ( OTCQB:MMEDF ) : 1H Net and comprehensive loss of $5.8M. Total assets at June 30, 2020 were $29.8M, including $24.0M cash, which will be used primarily to execute the company's multiple clinical trials. Press Release More news on: Mind Medicine (MindMed) Inc., Earning...
NEW YORK , Aug. 14, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30 , 2020. Complete financial st...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 9, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Com...
Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his stat...